Several gene-targeted therapies for PD are currently in development [137], particularly for PD patients carrying glucosylceramidase β (GBA) or leucine-rich repeat kinase-2 (LRRK2) pathogenic variants (www.clinicaltrials.gov, accessed on 10 July 2021). The gene discussed is LRRK2; the disease is Parkinson disease.